Presentation
The European Diabetes Study Centre (Centre européen d'étude du diabète – CeeD) was set up in 1991 in response to the worrying rise in diabetes cases by Pr Michel Pinget, a diabetologist and Professor Emeritus at the University of Strasbourg.
With the patient at the heart of its concerns, the CeeD stands out from other research laboratories due to its comprehensive strategy in the fight against diabetes:
- Research and development with its laboratory and start-up called ILONOV
- Prevention through training for healthcare professionals, screening and lectures for the general public
The CeeD is also:
- The sponsor of the public initiative called Defeating Diabetes (Vaincre le diabète) (prevention and support for research)
- Recognised as an "organisation of public utility" (Reconnu de mission d'utilité publique)
- ISO9001 : 15 certified
- The sponsor of a project selected by the City and Eurometropole of Strasbourg as part of the Health Territory of Tomorrow (Territoire de Santé de Demain) project, winner of the PIA 3 programme
- A founding member, with the EMS in particular, of the "Cities for Better Health" programme, an international programme aimed at reducing the impact of urban life on the development of type 2 diabetes
- An active member of the PRIESM association, a digital innovation structure in the Grand Est region
Research topics
Following the discovery of Myokine X as part of its projects, CeeD is now working on 2 major research topics.
Topic 1 - Type 1 diabetes and pancreatic islet transplantation
Although cell therapy enables type 1 diabetic patients to reactivate insulin production, it still presents numerous obstacles and remains reserved for the most serious cases. The CeeD hopes to optimise this procedure using Myokin X by improving the survival and function of islets at different stages of transplantation.
Topic 2 - Type 2 diabetes and related metabolic diseases
CeeD is now looking to determine whether Myokin X can also act on the various insulin-sensitive organs to improve their response to insulin and enable them to restore blood sugar levels while preventing the complications of type 2 diabetes that develop in these organs. This is a major challenge given the ever-increasing prevalence of T2DM.
Major events and works
- 2023: publication of the work "Myokines: Crosstalk and Consequences on Liver Physiopathology" in the journal Nutrients.
- 2022: publication of the work "Crosstalk Communications Between Islet Cells and Insulin Target Tissue: The Hidden Face of Iceberg" in the journal Frontiers in Endocrinology. This article summarises the foundations of CeeD's research projects.
- 2020: commercialisation of research with the creation of the ILONOV start-up to develop therapeutic solutions based on discoveries made on muscle by the CeeD.
- 2020: publication of the work "A circular RNA generated from an intron of the insulin gene controls insulin secretion" in the journal Nature Communications.
- 2019: publication of the work "Insights on the Role of Putative Muscle-Derived Factors on Pancreatic Beta Cell Function. Front Physiol" in the journal Frontiers in Physiology.
- 2019: publication of the collaborative work "Lymphocyte Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development" in the journal Cell metabolism (Guay C et al.).
- 2018: publication of work on muscle-pancreas cross-communication in the journal Scientific Reports (Nature Publishing Group): "Angiogenin and Osteoprotegerin are type II muscle specific myokines protecting pancreatic beta-cells against proinflammatory cytokines" (S. Rutti et al.).
Publication of 2 books:
- Diabetes. Mieux le comprendre pour mieux vivre
- Regards croisés sur le diabète